Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

Summary

The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular carcinoma. The study is also looking at the safety of TAC-101 following treatment with Sorafenib.

Timeline

Start

2008-08-01

Primary completion

2010-05-10

Completion

2010-05-10

Outcome

Outcome not reported

Stopped: “Terminated due to safety concerns”

Drugs

Indications